Symbols / GNLX $2.54 -0.78% Genelux Corporation
GNLX Chart
About
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Fundamentals
Scroll to Statements| Market Cap | 113.81M | Enterprise Value | 99.80M | Income | -32.15M | Sales | 8.00K | Book/sh | 0.31 | Cash/sh | 0.33 |
| Dividend Yield | — | Payout | 0.00% | Employees | 25 | IPO | — | P/E | — | Forward P/E | -3.09 |
| PEG | — | P/S | 14225.84 | P/B | 8.30 | P/C | — | EV/EBITDA | -3.03 | EV/Sales | 12474.51 |
| Quick Ratio | 2.35 | Current Ratio | 2.43 | Debt/Eq | 14.60 | LT Debt/Eq | — | EPS (ttm) | -0.86 | EPS next Y | -0.82 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-03-19 | ROA | -77.25% | ROE | -170.00% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | -1176.50% | Profit Margin | 0.00% | Shs Outstand | 44.81M | Shs Float | 36.15M | Short Float | 7.12% |
| Short Ratio | 17.03 | Short Interest | — | 52W High | 8.54 | 52W Low | 2.25 | Beta | 0.46 | Avg Volume | 198.26K |
| Volume | 118.79K | Target Price | $17.50 | Recom | None | Prev Close | $2.56 | Price | $2.54 | Change | -0.78% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-20 | main | Benchmark | Speculative Buy → Speculative Buy | $20 |
| 2025-10-21 | init | Lake Street | — → Buy | $16 |
| 2025-07-21 | init | LUCID CAPITAL MARKETS | — → Buy | $10 |
| 2025-05-08 | main | Benchmark | Speculative Buy → Speculative Buy | $23 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-11-15 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-29 | init | Guggenheim | — → Buy | $8 |
| 2024-08-27 | init | Roth MKM | — → Buy | $10 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-06-03 | reit | Benchmark | Speculative Buy → Speculative Buy | $25 |
| 2024-05-31 | main | Benchmark | Speculative Buy → Speculative Buy | $25 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-04-03 | reit | Benchmark | Speculative Buy → Speculative Buy | $30 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2023-11-27 | init | HC Wainwright & Co. | — → Buy | $35 |
| 2023-11-24 | main | Benchmark | Speculative Buy → Speculative Buy | $30 |
| 2023-09-12 | init | Maxim Group | — → Buy | $40 |
| 2023-06-09 | main | Benchmark | Speculative Buy → Speculative Buy | $38 |
| 2023-05-18 | init | Brookline Capital | — → Hold | $25 |
- GNLX (Genelux Corporation) falls 2.46% after Q4 2025 EPS lands below analyst consensus estimates. - Gamma Squeeze - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 21
- GNLX SEC Filings - Genelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 14
- Genelux Corporation (GNLX) Stock: Technical Signals (Technical Weakness) 2026-04-20 - Hot Momentum - Xã Vĩnh Công Mon, 20 Apr 2026 14
- $GNLX stock is down 30% today. Here's what we see in our data. - Quiver Quantitative hu, 06 Nov 2025 08
- Is Genelux Corporation (GNLX) Stock Good for Short Term | Price at $2.45, Down 7.20% - Stock Community Signals - Cổng thông tin điện tử Tỉnh Sơn La hu, 09 Apr 2026 07
- Cappello, Genelux CTO, sells $2192 in GNLX stock - Investing.com hu, 26 Mar 2026 07
- Genelux Corporation Announces Proposed Public Offering of Common Stock - Yahoo Finance Wed, 07 Jan 2026 08
- Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st ue, 06 Jan 2026 08
- $GNLX stock is down 16% today. Here's what we see in our data. - Quiver Quantitative hu, 08 Jan 2026 08
- Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com hu, 26 Mar 2026 07
- Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - Yahoo Finance Sun, 05 Oct 2025 07
- Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock - Quiver Quantitative hu, 08 Jan 2026 08
- Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan Wed, 07 Jan 2026 08
- Genelux (NASDAQ: GNLX) SVP sells 906 shares to cover RSU taxes - Stock Titan hu, 26 Mar 2026 07
- Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan Mon, 05 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.01
+0.00%
|
0.01
-95.29%
|
0.17
-98.46%
|
11.07
|
| Operating Revenue |
|
0.01
+0.00%
|
0.01
-95.29%
|
0.17
-98.46%
|
11.07
|
| Operating Expense |
|
33.22
+4.79%
|
31.70
+30.28%
|
24.34
+72.82%
|
14.08
|
| Research And Development |
|
19.85
+4.49%
|
19.00
+48.81%
|
12.77
+40.64%
|
9.08
|
| Selling General And Administration |
|
13.37
+5.23%
|
12.71
+9.84%
|
11.57
+131.22%
|
5.00
|
| General And Administrative Expense |
|
13.37
+5.23%
|
12.71
+9.84%
|
11.57
+131.22%
|
5.00
|
| Salaries And Wages |
|
8.49
+9.87%
|
7.73
+14.13%
|
6.77
+89.85%
|
3.57
|
| Other Gand A |
|
4.01
-0.05%
|
4.01
+7.88%
|
3.72
+237.39%
|
1.10
|
| Total Expenses |
|
33.22
+4.79%
|
31.70
+30.28%
|
24.34
+72.82%
|
14.08
|
| Operating Income |
|
-33.21
-4.79%
|
-31.70
-31.16%
|
-24.16
-702.02%
|
-3.01
|
| Total Operating Income As Reported |
|
-33.21
-4.79%
|
-31.70
-31.16%
|
-24.16
-702.02%
|
-3.01
|
| EBITDA |
|
-32.64
-6.00%
|
-30.79
-16.39%
|
-26.46
-1428.42%
|
-1.73
|
| Normalized EBITDA |
|
-32.64
-4.74%
|
-31.16
-19.60%
|
-26.05
-1174.08%
|
-2.04
|
| Reconciled Depreciation |
|
0.57
-36.43%
|
0.90
-11.30%
|
1.02
+5.17%
|
0.97
|
| EBIT |
|
-33.21
-4.79%
|
-31.70
-15.36%
|
-27.48
-917.97%
|
-2.70
|
| Total Unusual Items |
|
0.00
-100.00%
|
0.37
+192.04%
|
-0.40
-228.03%
|
0.31
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-100.00%
|
0.37
+192.04%
|
-0.40
-228.03%
|
0.31
|
| Special Income Charges |
|
0.00
-100.00%
|
0.37
+192.04%
|
-0.40
-228.03%
|
0.31
|
| Other Special Charges |
|
—
|
-0.37
-192.04%
|
0.40
+228.03%
|
-0.31
|
| Net Income |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Pretax Income |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-588.99%
|
-4.11
|
| Net Non Operating Interest Income Expense |
|
1.07
-26.63%
|
1.46
+139.06%
|
-3.73
-164.91%
|
-1.41
|
| Interest Expense Non Operating |
|
—
|
0.00
-100.00%
|
0.82
-41.62%
|
1.41
|
| Net Interest Income |
|
1.07
-26.63%
|
1.46
+139.06%
|
-3.73
-164.91%
|
-1.41
|
| Interest Expense |
|
—
|
0.00
-100.00%
|
0.82
-41.62%
|
1.41
|
| Interest Income Non Operating |
|
1.07
-26.63%
|
1.46
+497.13%
|
0.24
|
0.00
|
| Interest Income |
|
1.07
-26.63%
|
1.46
+497.13%
|
0.24
|
0.00
|
| Other Income Expense |
|
—
|
0.37
+192.04%
|
-0.40
-228.03%
|
0.31
|
| Tax Provision |
|
—
|
—
|
0.00
-100.00%
|
1.10
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.07
|
| Net Income Including Noncontrolling Interests |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Net Income From Continuing Operation Net Minority Interest |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Net Income From Continuing And Discontinued Operation |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Net Income Continuous Operations |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Normalized Income |
|
-32.15
-6.30%
|
-30.24
-8.40%
|
-27.89
-411.36%
|
-5.46
|
| Net Income Common Stockholders |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Diluted EPS |
|
—
|
-0.95
+18.10%
|
-1.16
-425.08%
|
-0.22
|
| Basic EPS |
|
—
|
-0.95
+18.10%
|
-1.16
-425.08%
|
-0.22
|
| Basic Average Shares |
|
—
|
31.45
+28.74%
|
24.43
+3.31%
|
23.65
|
| Diluted Average Shares |
|
—
|
31.45
+28.74%
|
24.43
+3.31%
|
23.65
|
| Diluted NI Availto Com Stockholders |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Insurance And Claims |
|
0.87
-9.94%
|
0.97
-10.39%
|
1.08
+222.75%
|
0.33
|
| Total Other Finance Cost |
|
—
|
—
|
3.15
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
19.03
-45.19%
|
34.72
+24.46%
|
27.89
|
| Current Assets |
|
15.13
-52.04%
|
31.55
+30.35%
|
24.20
|
| Cash Cash Equivalents And Short Term Investments |
|
14.60
-52.76%
|
30.89
+33.22%
|
23.19
|
| Cash And Cash Equivalents |
|
5.33
-37.73%
|
8.56
-9.06%
|
9.42
|
| Cash Equivalents |
|
—
|
7.58
-4.37%
|
7.92
|
| Cash Financial |
|
—
|
0.99
-33.94%
|
1.49
|
| Other Short Term Investments |
|
9.26
-58.52%
|
22.33
+62.13%
|
13.77
|
| Prepaid Assets |
|
—
|
—
|
—
|
| Other Current Assets |
|
0.54
-18.07%
|
0.65
-35.47%
|
1.01
|
| Total Non Current Assets |
|
3.90
+23.01%
|
3.17
-14.15%
|
3.69
|
| Net PPE |
|
3.75
+22.01%
|
3.08
-14.51%
|
3.60
|
| Gross PPE |
|
7.68
+13.61%
|
6.76
-4.07%
|
7.05
|
| Accumulated Depreciation |
|
-3.93
-6.60%
|
-3.68
-6.81%
|
-3.45
|
| Properties |
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.28
+0.00%
|
0.28
+0.00%
|
0.28
|
| Construction In Progress |
|
2.35
+80.68%
|
1.30
+30.55%
|
0.99
|
| Other Properties |
|
4.50
-2.77%
|
4.63
-11.32%
|
5.22
|
| Leases |
|
0.56
+0.00%
|
0.56
+0.00%
|
0.56
|
| Non Current Deferred Assets |
|
—
|
—
|
0.00
|
| Other Non Current Assets |
|
0.14
+56.52%
|
0.09
+0.00%
|
0.09
|
| Total Liabilities Net Minority Interest |
|
7.48
-11.36%
|
8.44
+0.26%
|
8.42
|
| Current Liabilities |
|
6.22
-9.82%
|
6.90
+5.32%
|
6.55
|
| Payables And Accrued Expenses |
|
5.80
-11.80%
|
6.57
+11.40%
|
5.90
|
| Payables |
|
4.36
-21.76%
|
5.57
+47.20%
|
3.78
|
| Accounts Payable |
|
4.36
-21.76%
|
5.57
+47.20%
|
3.78
|
| Current Accrued Expenses |
|
1.44
+43.43%
|
1.00
-52.57%
|
2.12
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.43
+29.79%
|
0.33
-49.62%
|
0.65
|
| Current Debt |
|
—
|
—
|
—
|
| Other Current Borrowings |
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.43
+29.79%
|
0.33
-49.62%
|
0.65
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
|
| Other Current Liabilities |
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
1.26
-18.26%
|
1.54
-17.52%
|
1.87
|
| Long Term Debt And Capital Lease Obligation |
|
1.26
-18.26%
|
1.54
-17.52%
|
1.87
|
| Long Term Debt |
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
1.26
-18.26%
|
1.54
-17.52%
|
1.87
|
| Stockholders Equity |
|
11.54
-56.06%
|
26.27
+34.93%
|
19.47
|
| Common Stock Equity |
|
11.54
-56.06%
|
26.27
+34.93%
|
19.47
|
| Capital Stock |
|
0.04
+8.57%
|
0.04
+29.63%
|
0.03
|
| Common Stock |
|
0.04
+8.57%
|
0.04
+29.63%
|
0.03
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
| Share Issued |
|
38.57
+9.70%
|
35.16
+29.16%
|
27.22
|
| Ordinary Shares Number |
|
38.14
+9.82%
|
34.73
+29.64%
|
26.79
|
| Treasury Shares Number |
|
0.43
+0.00%
|
0.43
+0.00%
|
0.43
|
| Additional Paid In Capital |
|
295.47
+6.28%
|
278.00
+15.17%
|
241.39
|
| Retained Earnings |
|
-283.54
-12.79%
|
-251.39
-13.48%
|
-221.52
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
-85.94%
|
0.06
+357.14%
|
0.01
|
| Treasury Stock |
|
0.43
+0.00%
|
0.43
+0.00%
|
0.43
|
| Other Equity Adjustments |
|
0.01
-85.94%
|
0.06
+357.14%
|
0.01
|
| Total Equity Gross Minority Interest |
|
11.54
-56.06%
|
26.27
+34.93%
|
19.47
|
| Total Capitalization |
|
11.54
-56.06%
|
26.27
+34.93%
|
19.47
|
| Working Capital |
|
8.90
-63.87%
|
24.64
+39.64%
|
17.65
|
| Invested Capital |
|
11.54
-56.06%
|
26.27
+34.93%
|
19.47
|
| Total Debt |
|
1.69
-9.80%
|
1.87
-25.84%
|
2.52
|
| Net Debt |
|
—
|
—
|
—
|
| Capital Lease Obligations |
|
1.69
-9.80%
|
1.87
-25.84%
|
2.52
|
| Net Tangible Assets |
|
11.54
-56.06%
|
26.27
+34.93%
|
19.47
|
| Tangible Book Value |
|
11.54
-56.06%
|
26.27
+34.93%
|
19.47
|
| Current Notes Payable |
|
—
|
—
|
0.00
|
| Interest Payable |
|
—
|
—
|
0.00
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-25.27
-19.03%
|
-21.23
-4.70%
|
-20.27
-467.77%
|
-3.57
|
| Cash Flow From Continuing Operating Activities |
|
-25.27
-19.03%
|
-21.23
-4.70%
|
-20.27
-467.77%
|
-3.57
|
| Net Income From Continuing Operations |
|
-32.15
-7.62%
|
-29.87
-5.56%
|
-28.30
-443.44%
|
-5.21
|
| Depreciation Amortization Depletion |
|
0.57
-36.43%
|
0.90
-11.30%
|
1.02
+5.17%
|
0.97
|
| Depreciation |
|
0.57
-36.43%
|
0.90
-11.30%
|
1.02
+5.17%
|
0.97
|
| Depreciation And Amortization |
|
0.57
-36.43%
|
0.90
-11.30%
|
1.02
+5.17%
|
0.97
|
| Other Non Cash Items |
|
0.90
-46.36%
|
1.67
+5.35%
|
1.59
+2937.50%
|
-0.06
|
| Stock Based Compensation |
|
6.68
+10.00%
|
6.07
+16.64%
|
5.20
+115.49%
|
2.42
|
| Operating Gains Losses |
|
—
|
—
|
3.55
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
3.15
|
—
|
| Change In Working Capital |
|
-1.05
-239.28%
|
0.75
+122.89%
|
-3.28
-94.03%
|
-1.69
|
| Change In Prepaid Assets |
|
0.07
-81.62%
|
0.36
-25.67%
|
0.48
+387.50%
|
-0.17
|
| Change In Payables And Accrued Expense |
|
-0.78
-174.30%
|
1.04
+133.96%
|
-3.07
-196.09%
|
3.20
|
| Change In Accrued Expense |
|
0.44
+139.35%
|
-1.11
-56.10%
|
-0.71
-180.75%
|
0.88
|
| Change In Payable |
|
-1.21
-156.26%
|
2.16
+191.43%
|
-2.36
-201.95%
|
2.31
|
| Change In Account Payable |
|
-1.21
-156.26%
|
2.16
+191.43%
|
-2.36
-201.95%
|
2.31
|
| Change In Other Working Capital |
|
—
|
—
|
-0.17
+96.07%
|
-4.33
|
| Change In Other Current Liabilities |
|
-0.34
+48.23%
|
-0.65
-24.47%
|
-0.52
-34.45%
|
-0.39
|
| Investing Cash Flow |
|
12.14
+249.32%
|
-8.13
+44.78%
|
-14.72
-29948.98%
|
-0.05
|
| Cash Flow From Continuing Investing Activities |
|
12.14
+249.32%
|
-8.13
+44.78%
|
-14.72
-29948.98%
|
-0.05
|
| Net PPE Purchase And Sale |
|
-1.10
-188.19%
|
-0.38
+62.83%
|
-1.02
-1991.84%
|
-0.05
|
| Purchase Of PPE |
|
-1.10
-188.19%
|
-0.38
+62.83%
|
-1.02
-1991.84%
|
-0.05
|
| Capital Expenditure |
|
-1.10
-188.19%
|
-0.38
+62.83%
|
-1.02
-1991.84%
|
-0.05
|
| Net Investment Purchase And Sale |
|
13.24
+270.83%
|
-7.75
+43.43%
|
-13.70
|
0.00
|
| Purchase Of Investment |
|
-18.26
+37.03%
|
-29.00
-111.69%
|
-13.70
|
0.00
|
| Sale Of Investment |
|
31.50
+48.24%
|
21.25
|
0.00
|
—
|
| Financing Cash Flow |
|
9.89
-65.29%
|
28.51
-35.24%
|
44.02
+9309.21%
|
-0.48
|
| Cash Flow From Continuing Financing Activities |
|
9.89
-65.29%
|
28.51
-35.24%
|
44.02
+9309.21%
|
-0.48
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
0.21
-77.84%
|
0.97
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
0.90
-18.18%
|
1.10
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-0.69
-426.92%
|
-0.13
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
1.10
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.13
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.13
|
| Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
0.90
-18.18%
|
1.10
|
| Short Term Debt Payments |
|
—
|
0.00
+100.00%
|
-0.69
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
0.21
-80.45%
|
1.10
|
| Net Common Stock Issuance |
|
9.66
-65.29%
|
27.82
-29.83%
|
39.65
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.24
-65.41%
|
0.69
-84.58%
|
4.46
+3619.17%
|
0.12
|
| Net Other Financing Charges |
|
—
|
—
|
-0.30
+80.68%
|
-1.57
|
| Changes In Cash |
|
-3.23
-278.90%
|
-0.85
-109.46%
|
9.02
+320.13%
|
-4.10
|
| Beginning Cash Position |
|
8.56
-9.06%
|
9.42
+2272.29%
|
0.40
-91.17%
|
4.50
|
| End Cash Position |
|
5.33
-37.73%
|
8.56
-9.06%
|
9.42
+2272.29%
|
0.40
|
| Free Cash Flow |
|
-26.37
-22.01%
|
-21.61
-1.45%
|
-21.30
-488.40%
|
-3.62
|
| Interest Paid Supplemental Data |
|
—
|
0.00
-100.00%
|
0.07
-72.73%
|
0.26
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-0.23
+70.15%
|
-0.76
-1120.97%
|
-0.06
|
0.00
|
| Change In Interest Payable |
|
—
|
0.00
-100.00%
|
0.02
-97.52%
|
0.89
|
| Common Stock Issuance |
|
9.66
-65.29%
|
27.82
-29.83%
|
39.65
|
0.00
|
| Issuance Of Capital Stock |
|
9.66
-65.29%
|
27.82
-29.83%
|
39.65
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-26 View
- 42026-03-26 View
- 42026-03-26 View
- 42026-03-26 View
- 8-K2026-03-19 View
- 10-K2026-03-19 View
- 42026-03-03 View
- 8-K2026-02-02 View
- 8-K2026-01-08 View
- 42026-01-07 View
- 8-K2026-01-05 View
- 8-K2026-01-02 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-09 View
- 42025-12-02 View
- 10-Q2025-11-05 View
- 42025-09-03 View
- 42025-09-03 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|